Evidence map›Paper›PMID 30555234›Full record

ArticleInternational journal of nanomedicine2018

Surface engineered polyanhydride-based oral

Sankar Renu, Ashley D Markazi, Santosh Dhakal, Yashavanth S Lakshmanappa, Suren R Gourapura, Revathi Shanmugasundaram, Sujata Senapati, Balaji Narasimhan, Ramesh K Selvaraj, Gourapura J Renukaradhya

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nanomedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 41 citations in OpenAlex.

  1. Design of an oral vaccine againstThe veterinary quarterly · 2026
    Article
  2. Article
  3. Orally delivered chitosan-basedFrontiers in immunology · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Current Progress and Challenges in the Study of Adjuvants for Oral Vaccines.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023
    Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. A Novel Approach againstVaccines · 2021
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Sankar RenuFood Animal Health Research Program, Ohio Agricultural Research and Development Center, The Ohio State University, Wooster, OH 44691, USA, gourapura.1@osu.edu.
Ashley D MarkaziDepartment of Animal Sciences, Ohio Agricultural Research and Development Center, The Ohio State University, Wooster, OH 44691, USA.
Santosh DhakalFood Animal Health Research Program, Ohio Agricultural Research and Development Center, The Ohio State University, Wooster, OH 44691, USA, gourapura.1@osu.edu.
Yashavanth S LakshmanappaFood Animal Health Research Program, Ohio Agricultural Research and Development Center, The Ohio State University, Wooster, OH 44691, USA, gourapura.1@osu.edu.
Suren R GourapuraFood Animal Health Research Program, Ohio Agricultural Research and Development Center, The Ohio State University, Wooster, OH 44691, USA, gourapura.1@osu.edu.
Revathi ShanmugasundaramDepartment of Animal Sciences, Ohio Agricultural Research and Development Center, The Ohio State University, Wooster, OH 44691, USA.
Sujata SenapatiDepartment of Chemical and Biological Engineering, Iowa State University, Ames, IA 50011, USA.
Balaji NarasimhanDepartment of Chemical and Biological Engineering, Iowa State University, Ames, IA 50011, USA.
Ramesh K SelvarajDepartment of Poultry Science, University of Georgia, Athens, GA 30602, USA, selvaraj@uga.edu.
Gourapura J RenukaradhyaFood Animal Health Research Program, Ohio Agricultural Research and Development Center, The Ohio State University, Wooster, OH 44691, USA, gourapura.1@osu.edu.
The Ohio State University · USIowa State University · USUniversity of Georgia · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSalmonellosis is a severe economic threat in poultry and a public health concern. Currently available vaccines are ineffective, and thus, developing effective oral MATERIALS AND

methodsWe designed a

resultsThe candidate vaccine was resistant in acidic microenvironment and had ideal physicochemical properties for oral delivery in terms of particle size, charge, morphology, biocompatibility, and pH stability. In vitro, in vivo, and ex vivo studies showed that F-protein surface-anchored nanoparticles were better targeted to chicken immune cells in peripheral blood and splenocytes and intestinal Peyer's patch sites. In layer chickens inoculated orally with OMPs-F-PNPs, substantially higher OMPs-specific IgG response and secretion of Th1 cytokine IFN-γ in the serum, enhanced CD8

conclusionThis pilot in vivo study demonstrated the targeted delivery of OMPs-F-PNPs to ileum mucosal immune sites of chickens and induced specific immune response to mitigate

Indexed as

AdhesivenessAnimalsAntibody FormationChickensCytokinesFlagellaFluorescenceImmunity, CellularMucusNanoparticlesPolyanhydridesPorinsRNA, MessengerSalmonellaSalmonella VaccinesSurface PropertiesCytokinesOmpF proteinPolyanhydridesPorinsRNA, MessengerSalmonella VaccinesVaccines, Subunitchickensileumoral deliverypolyanhydride nanoparticlesSalmonella antigens

Identifiers

PMID30555234
PMCPMC6280892
OpenAlexW2903128791

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.